Apellis APLS 深 沪
等待开盘 08-20 09:30:00 美东时间
41.03
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 41.03
- 总市值 525.18万
- 52周最高 41.14
- 市盈率 静 237.99
- 换手率 0.00%
- 52周最低 16.61
- 委 比 0.00%
- 总股本 0.00亿
- 历史最高 94.75
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.45
- 每 手 1
- 风险率 7.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Annexon (ANNX) Q2 2026 Earnings Call: ARCHER II Expanded, BLA Filing on Track
Annexon’s Q2 2026 earnings call covered ARCHER II’s new month 24 endpoint, initial FORWARD data and a planned Q4 tanruprubart BLA filing.
08-17 08:00
Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer
Kailera Therapeutics appoints Nur Nicholson as Chief Technology Officer to oversee manufacturing and supply chain strategy as the company advances its obesity treatment pipeline. Nicholson, with nearly three decades of experience in pharmaceutical operations, will help ensure scalable and reliable supply capabilities to support the commercialization of Kailera's products, including its lead candidate ribupatide injection in global Phase 3 trials.
08-11 11:00
老药衰退新药接棒！收购驱动转型初见成效，百健(BIIB.US)上调全年营收指引
百健(BIIB.US)公布的季度营收和经调整后收益均超出了分析师的预期，这得益于新收购的肾脏及眼科疾病药物的销售增长。
07-29 20:10
渤健：尼达姆与公司高层会议核心要点
Needham分析师阿米·法迪亚在与渤健（Biogen）管理层会面后，将其目标价从255美元上调至256美元，维持“买入”评级。 核心业务相关要点： Spi...
06-29 23:32
Biogen's Base Is Declining — But 8 Pipeline Readouts Could Flip The Story
Biogen analyst upgraded to Buy, cites key growth drivers as Leqembi, Spinraza, Syfovre, and Empavelli and other catalysts.
06-09 00:08
Biogen, UCB lupus drug dapirolizumab pegol meets phase 3 goal
UCB and Biogen (BIIB) on Monday said that their investigational drug dapirolizumab pegol met the primary endpoint in a phase 3 trial for systemic lupus erythematosus, with 50% of patients achieving a ...
06-01 13:25
超7亿美金闪电融资，自免新星正面硬刚巨头
本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。 新锐自免...
05-20 09:34
大洗牌前夜：翻阅十大药企最新财报后，我看见权力正在转移
2026年第一季度的财报已基本出齐，全球制药业的竞争位次经历了一轮深刻的重构。将三组关键数据并列观察，格局的轮廓便会自动浮现。 第一组：礼来单季营收198亿美元...
05-18 16:29
